PDS in Retinal Diseases: Practical Advice on Education and Training

Video

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

Transcript:

Chirag Jhaveri, MD: As we all start performing more of these surgeries, since it is now approved for the use of neovascular AMD [age-related macular degeneration], it is going to be very important to review videos prior to implantation of the PDS [port delivery system] in our patients. In addition, there are surgical simulators that can give you great hands-on experience. I anticipate many of these simulators to be available at many of our meetings, including ASRS [the American Society of Retina Specialists] and AAO [American Academy of Ophthalmology]. It’s also very important to have a good relationship with your surgical device liaison. These individuals are going to be very helpful in guiding you through your first few surgeries. They will be present as needed in your operating room, and they will definitely be there for your first few cases. I highly recommend utilizing them, as they’re wonderful resources to help guide you through your first few cases.

The surgical device liaisons are individuals who you can get in touch with through the company representatives. They are individuals who are there for your resource, and to help guide you in learning any of the tips, pearls, and steps that you would like to discuss for the PDS implantation.

A detailed description of both the implantation and the refill is going through publication approval. These will also have associated videos. In addition, if you would like more videos, you can also discuss this with your surgical device liaison, and they’re happy to provide additional teaching techniques and videos.

Transcript edited for clarity.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.